Kolon’s Cell-Based Gene Therapy Fails Phase 3 Osteoarthritis Trial
Kolon TissueGene’s phase 3 trial found its osteoarthritis therapy did not improve knee pain or function versus placebo, leaving the biotech to await results from a second late-stage study before deciding the program’s future.
Key Points
- Kolon TissueGene’s phase 3 trial of TG-C in knee osteoarthritis missed its co-primary endpoints and all key secondary endpoints.
- The study enrolled 531 patients across 27 U.S. sites and compared intra-articular TG-C injections against placebo.
- Kolon plans to decide the future of the program after data from a second phase 3 trial expected in October.
Kolon TissueGene, a Korean-based biotech company, announced that its cell-based gene therapy, TG-C, failed to meet the main goals of a phase 3 trial in osteoarthritis of the knee. After one year, patients who received TG-C showed no statistically significant improvement in knee pain or function versus placebo. The trial also missed all key secondary endpoints.
Stay updated on Gene Therapy news
Thanks! Your signup has been saved.
For context, TG-C contains human allogeneic (donor derived) chondrocytes and an irradiated human embryonic kidney-derived cell line stably expressing TGF-β1. South Korean regulators approved the therapy in 2017, but withdrew that approval two years later after a mix-up over the type of cells used in the treatment.
Trial design and what comes next
Kolon enrolled 531 patients at 27 sites in the U.S. The trial compared intra-articular injections of TG-C with placebo. Enrollment began four years after the company registered the study, following an FDA hold.
Attention now shifts to Kolon’s second phase 3 trial, which is expected to report data in October this year. That study has the same treatment arms and co-primary endpoints as the failed trial, along with nearly identical inclusion and exclusion criteria. Kolon said it will decide the next steps for the program after reviewing those results.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
CIRM Approves $662M Regen Med Funding, Largest in its History
FDA Reverses Decision on Regenxbio’s Gene Therapy for Hunter’s Syndrome, Supporting BLA Resubmission for Accelerated Approval
Altman-Backed Regenerative Medicine Startup, Retro Biosciences, Closes Funding Round at $1.8B Valuation
Sana Biotechnology and Mayo Clinic Partner Up on Type 1 Diabetes Stem Cell-Derived Therapy, Phase 1 Potentially This YearEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
